Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has
developed a revolutionary tool to automate panel design. The
company has expanded the capabilities of the Panel Builder tool
within its Cytek® Cloud digital ecosystem with the addition of
SpectroPanel™ tool, a proprietary new intelligent algorithm which
suggests optimized panels in minutes.
Optimized for Cytek’s Full Spectrum Profiling™
(FSP™) technology, the SpectroPanel tool automates the assignment
of fluorochromes to markers, removing the labor-intensive manual
process. This allows scientists to jumpstart their panel design
process.
With over 11,000 users and counting, Cytek Cloud
is a vital resource in the research community. Supporting full
spectrum flow cytometry research from panel design to experiment
setup to data acquisition, Cytek Cloud enables researchers to
design panels with ease, taking into account antigen density,
marker expression, and reagent availability. Users can also access
Cytek cFluor® and Tonbo™ reagents within the platform, via built-in
Cytek and partner catalogs.
Cytek Cloud consists of a suite of integrated,
online software tools that streamline workflows – combining all
spectral panel design tools in one place and allowing users to
prepare experiments remotely. Cytek Cloud accelerates the time to
insight for a wide range of applications, including immunology,
oncology, infectious diseases, and inflammatory diseases. The Panel
Builder tool features an easy-to-use panel wizard that guides panel
design with the ability to search and modify pre-designed panels
and Optimized Multicolor Immunofluorescence Panels (OMIPs). Users
can easily build and share panels.
Wenbin Jiang, Ph.D., CEO of Cytek Biosciences
said, “This is a major milestone for us – and for the entire
research community. What used to take days or weeks can now be done
in minutes. The complexity and labor involved in panel design often
deters users from utilizing flow cytometry. By simplifying this
process, we anticipate increased adoption of FSP-based instruments
across the industry. At Cytek, we pride ourselves on evolving our
offerings to meet the needs of our users, and the SpectroPanel tool
is a direct response to their requests for assistance with panel
design. Looking ahead, we plan to expand Cytek Cloud’s
capabilities, including enhanced data management, sharing, and
analysis features."
For more information, please visit
https://cytekbio.com/pages/cytek-cloud.
About Cytek Biosciences,
Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell
analysis solutions company advancing the next generation of cell
analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail
preparation system, and reagents, software and services to provide
a comprehensive and integrated suite of solutions for its
customers. Cytek headquarters are in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, SpectroPanel, Full Spectrum Profiling,
FSP, cFluor, Cytek Aurora, Northern Lights, NL-CLC, Cytek Orion,
Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s business, product plans, strategies
and market opportunities, including expectations that by
simplifying the panel design process, adoption of FSP-based
instruments will increase across the industry and Cytek’s plan to
expand Cytek Cloud’s capabilities, including enhanced data
management, sharing, and analysis features. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management.
These statements also deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to global economic, political and market conditions;
competition; market acceptance of Cytek’s current and potential
products; Cytek’s dependence on certain sole and single source
suppliers; Cytek’s ability to manage the growth and complexity of
its organization; Cytek’s ability to manage relationships with key
customers and suppliers; Cytek’s ability to retain key employees;
and Cytek’s ability to continue to stay in compliance with its
material contractual obligations, applicable laws and regulations.
You should refer to the section entitled “Risk Factors” set forth
in Cytek’s most recent Quarterly Report on Form 10-Q filed with the
SEC and other filings Cytek makes with the SEC from time to time
for a discussion of important factors that may cause actual results
to differ materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Jul 2024 to Jul 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Jul 2023 to Jul 2024